Literature DB >> 22575050

Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities.

Seunghee Hong1, Jinhee Kim, Ju Hyeon Seo, Kyung Hee Jung, Soon-Sun Hong, Sungwoo Hong.   

Abstract

Tropomyosin-related kinase A (TrkA) is considered a promising target in the development of a therapeutic treatment of cancer and pain. In this study, we designed and synthesized a series of novel 7-azaindole-based Trk kinase inhibitors through the structure-based design strategy. By varying the functional groups at the 3 and 5 positions of a 7-azaindole scaffold, we studied the structure-activity relationships (SAR) profiles and identified a series of potent Trk inhibitors. Representative derivatives showed desirable activity in cellular proliferation and apoptosis assays. Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575050     DOI: 10.1021/jm3002982

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Blockage of tropomyosin receptor kinase a (TrkA) enhances chemo-sensitivity in breast cancer cells and inhibits metastasis in vivo.

Authors:  Ju Zhang; Lun-Shan Wang; Shu-Lai Ye; Peng Luo; Bao-Long Wang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

Authors:  Chengbin Yang; Xi Zhang; Yi Wang; Yongtai Yang; Xiaofeng Liu; Mingli Deng; Yu Jia; Yun Ling; Ling-Hua Meng; Yaming Zhou
Journal:  ACS Med Chem Lett       Date:  2017-07-26       Impact factor: 4.345

3.  Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities.

Authors:  Renaud Prudent; Émilie Vassal-Stermann; Chi-Hung Nguyen; Marjorie Mollaret; Jean Viallet; Agnès Desroches-Castan; Anne Martinez; Caroline Barette; Catherine Pillet; Glaucio Valdameri; Emmanuelle Soleilhac; Attilio Di Pietro; Jean-Jacques Feige; Marc Billaud; Jean-Claude Florent; Laurence Lafanechère
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  Azaindole therapeutic agents.

Authors:  Damoder Reddy Motati; Radhika Amaradhi; Thota Ganesh
Journal:  Bioorg Med Chem       Date:  2020-10-30       Impact factor: 3.641

5.  Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives.

Authors:  Pavel Starha; Jan Hošek; Ján Vančo; Zdeněk Dvořák; Pavel Suchý; Igor Popa; Gabriela Pražanová; Zdeněk Trávníček
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Scope and limitations of a DMF bio-alternative within Sonogashira cross-coupling and Cacchi-type annulation.

Authors:  Kirsty L Wilson; Alan R Kennedy; Jane Murray; Ben Greatrex; Craig Jamieson; Allan J B Watson
Journal:  Beilstein J Org Chem       Date:  2016-09-08       Impact factor: 2.883

Review 7.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

Review 8.  Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.

Authors:  Tingting Jiang; Guan Wang; Yao Liu; Lu Feng; Meng Wang; Jie Liu; Yi Chen; Liang Ouyang
Journal:  Acta Pharm Sin B       Date:  2020-05-23       Impact factor: 11.413

9.  Regioselective C-H sulfenylation of N-sulfonyl protected 7-azaindoles promoted by TBAI: a rapid synthesis of 3-thio-7-azaindoles.

Authors:  Jingyan Hu; Xiaoming Ji; Shuai Hao; Mingqin Zhao; Miao Lai; Tianbao Ren; Gaolei Xi; Erbin Wang; Juanjuan Wang; Zhiyong Wu
Journal:  RSC Adv       Date:  2020-08-27       Impact factor: 4.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.